Abstract:STRESZCZENIE Cel pracy. Zbadanie i ocena skuteczności klinicznej i bezpieczenstwa przeskornego plastra z klonidyną w leczeniu zespolu Tourette’a (TS). Material i metody. Grupa 130 dzieci w wieku od 2 do 15 lat z zespolem Tourette’a zostala zrandomizowana do dwoch grup: 71 dzieci z badanej grupy bylo leczonych plastrem przezskornym z klonidyną, zaś 59 z grupy kontrolnej – haloperidolem. Po czterech tygodniach leczenia skutecznośc kliniczna zostala oceniona za pomocą skali Yale Globar Tic Severity Scale (YGTSS). Skutecznośc krotkoterminowa, objawy uboczne leczenia zostaly ocenione pod koniec leczenia, zaś skutecznośc dlugoterminową, jak rowniez czestośc nawrotow oceniono po pol roku od zakonczenia leczenia. Wyniki. Punktacja YGTSS w obu grupach obnizyla sie po czterech tygodniach leczenia, ale grupa chorych leczonych klonidyną wykazala wiekszą redukcje tikow w ogolnej punktacji tikowej (61,7 ± 7,3%), niz grupa leczonych haloperidolem (40,8 ±6,5%; P<0,05). Średni wspolczynnik skuteczności przezskornego plastra z klonidyną wynosil 81,7% (skutecznośc u 58 chorych), podczas gdy w przypadku doustnego haloperidolu skutecznośc wynosila 66,1% (skutecznośc u 39 chorych) (p<0,05). Nie obserwowano powaznych objawow ubocznych w zadnej z badanych grup. Niewielkie objawy uboczne pod postacią spadku ciśnienia krwi i zawrotow glowy obserwowano u jednego pacjenta leczonego przezskornie klonidyną. W grupie leczonych haloperidolem obserwowano lagodną miotonie, nudności lub sennośc u sześciu chorych. Slowa kluczowe: zespol Tourett’a, dzieci, leczenie, przezskorne plastry klonidyny ABSTRACT Objective. To examine and evaluate the clinical efficacy and safety of clonidine transdermal patch in treating Tourette syndrome. (TS). Material and Methods. A total of 130 children aged from 2 to 15 years with TS were randomized into two groups: 71 patients in the treated group were treated with clonidine transdermal patch and 59 in the control group were treated with haloperidol. After 4 weeks of treatment, the clinical efficacy was assessed by the Yale Global Tic Severity Scale(YGTSS). The short-term efficacy and adverse reaction of treatment were assessed at the end of treatment, the longterm efficacy as well as the recurrent rate were evaluated half a year after the end of treatment. Results. The YGTSS score in both groups decreased after 4 weeks of treatment, but the clonidine transdermal patch group showed a higher reduction in the overall tic symptom scores (61.7 ± 7.3%) than that in the haloperidol group. (40.8 ±6.5%; P<0.05). The overall effective rate in Clonidine transdermal patch treatment was 81.7% (effective in 58 patients) and 66.1% to oral haloperidol (effective in 39 patients) (p<0.05). There were no severe adverse events in both groups, but mild side effects (decreased blood pressure and dizziness) were observed in 1 patient in the clonidine transdermal patch group. Mild hypermyotonia, drowsiness or lassitude as side effects occurred in 6 patients in the haloperidol group. Conclusion. Clonidine transdermal patch treatment in TS Chinese children was more effective with lower incidence of adverse reactions and lower recurrent rate as compared with haloperidol group. Clonidine represents a new therapeutic option for the treatment of tic disorder.

In Vitro and in Vivo Characterization of A Newly Developed Clonidine Transdermal Patch for Treatment of Attention Deficit Hyperactivity Disorder in Children

Study of the Percutaneous Permeability of Clonidine Transdermal Patch in Vitro

Clonidine Patch for Tourette Syndrome With Attention-Deficit/Hyperactivity Disorder

Randomized Double-Blind Multicentre Placebo-Controlled Clinical Trial of the Clonidine Adhesive Patch for the Treatment of Tic Disorders.

Effects of a newly developed transdermal clonidine delivery system (M-5041T) on EEG sleep-wake cycle in relation to plasma concentration in rabbits

Safety and efficacy of clonidine hydrochloride extended –release (CLON-XR) for treatment of attention deficit hyperactivity disorder in Chinese children and adolescents: a multi-center, placebo-controlled, randomized, double-blind study

Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects

Clonidine: a practical guide for usage in children

Antihypertensive effects of a new transdermal delivery system for clonidine in genetic and experimental hypertensive rats

Efficacy and safety of two different galenic formulations of a transdermal clonidine system in the treatment of hypertension

Antihypertensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously hypertensive rats

Combined hydroxyphenyl-modified adhesive with the ion-pair strategy for long-lasting delivery of clonidine in single-layer matrix-type patch

Patient acceptance of transdermal clonidine. A retrospective review of 25 patients

Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug–resin suspension as a sustained-release formulation

A New Poly(2-Hydroxy-3-phenoxypropylacrylate, 4-Hydroxybutyl Acrylate, Diethyl Maleate) Membrane Controlled Clonidine Linear Release in the Transdermal Drug Delivery System

Transdermal clonidine: therapeutic considerations

Establishment and Validation of a Transdermal Drug Delivery System for the Anti-Depressant Drug Citalopram Hydrobromide

One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension--a multicentre open label study. The Antihypertensive Patch Italian Study (APIS) Investigators

[Determination of Clonidine in Rabbit Plasma by HPLC-MS].

Efficacy of Clonidine Adhesive Patch for Patients With Tourette Syndrome: A Randomized, Double-blind, Placebo-Controlled, Multicenter Clinical Trial

Clinical Assessment of Treatment of Tourette Syndrome in Chinesechildren with Clonidine Transdermal Patch